Cancer clinical trials in the region Pays de la Loire

456 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Rectal cancer #NCT06402864 #2023-506885-30-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06943872 #2024-517131-52-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lymphoma #NCT05947851 #2022-501560-17-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 CLL & Richter's syndrome #NCT05947851 #2022-501560-17-01
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Colon cancer #NCT06107920 #2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
3 recruiting sites
CHU Rouen
Phase 3 Colon cancer #NCT05855200 #2023-503265-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSS/pMMR
9 recruiting sites
GlaxoSmithKline
Phase 3 Colon cancer Rectal cancer #NCT06293625
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
57 recruiting sites
CHU Dijon
Phase 3 Lung cancer #NCT06793215 #2024-518365-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Hoffmann-La Roche
Phase 3 Lung cancer #NCT06765109 #2024-517553-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF EGFR HER2 HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
11 recruiting sites
Nuvalent Inc.